Stockscreener 앱 받기
26.07
4.78%
-1.31
전일 마감가:
$27.38
열려 있는:
$27.39
하루 거래량:
337.42K
Relative Volume:
1.07
시가총액:
$1.17B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.04%
1개월 성능:
-0.61%
6개월 성능:
+117.43%
1년 성능:
+53.53%
1일 변동 폭
$25.99
$28.15
1주일 범위
$24.44
$28.15
52주 변동 폭
$4.17
$30.50
Septerna Inc Stock (SEPN) Company Profile
명칭
Septerna Inc
전화
650-338-3533
주소
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
SEPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
26.07 | 1.23B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | Raymond James | Strong Buy |
| 2025-12-15 | 개시 | Truist | Buy |
| 2025-11-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-06-23 | 개시 | H.C. Wainwright | Buy |
| 2025-02-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-19 | 개시 | JP Morgan | Overweight |
| 2024-11-19 | 개시 | TD Cowen | Buy |
| 2024-11-19 | 개시 | Wells Fargo | Overweight |
모두보기
Septerna Inc 주식(SEPN)의 최신 뉴스
Aug Reactions: Does Septerna Inc have a sustainable dividendInflation Watch & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Septerna (NASDAQ:SEPN) Shares Up 7.5%Still a Buy? - MarketBeat
Septerna to Present GPCR Pipeline Updates at JPM Conference - TipRanks
Septerna, Inc. Announces Key Developments at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Assessing Septerna (SEPN) Valuation After Recent Share Price Pullback And One Year 40.63% Return - Yahoo Finance
Septerna (NASDAQ:SEPN) Downgraded to “Buy” Rating by Wall Street Zen - Defense World
Septerna, Inc. (SEPN) Stock Analysis: Unraveling a 28.76% Potential Upside in Biotechnology - DirectorsTalk Interviews
Septerna, Inc. (NASDAQ:SEPN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Septerna Appoints Mark Wilson as Chief Legal Officer - The Globe and Mail
Will Septerna Inc. stock benefit from sector rotationMarket Growth Summary & AI Enhanced Market Trend Forecasts - Улправда
Why retail investors favor Septerna Inc. stockEarnings Risk Summary & Low Drawdown Trading Techniques - Улправда
What Wall Street predicts for Septerna Inc. stock priceMarket Growth Summary & Intraday High Probability Setup Alerts - ulpravda.ru
Septerna appoints Mark Wilson as chief legal officer By Investing.com - Investing.com South Africa
Septerna appoints Mark Wilson as chief legal officer - Investing.com
Septerna, Inc. Expands Leadership with New Chief Legal Officer - TradingView — Track All Markets
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer - The Manila Times
Septerna (NASDAQ:SEPN) Stock Price Down 6.3%What's Next? - MarketBeat
What analysts say about Septerna Inc stockDividend Yield Trends & AI-Based Predictions Available Free - earlytimes.in
Jones Trading initiates coverage of Septerna (SEPN) with buy recommendation - MSN
Jones Trading Initiates Coverage of Septerna (SEPN) with Buy Recommendation - Nasdaq
Septerna stock initiated with Buy rating at Jones Trading on GPCR pipeline By Investing.com - Investing.com South Africa
Septerna stock initiated with Buy rating at Jones Trading on GPCR pipeline - Investing.com Nigeria
Septerna (NASDAQ:SEPN) Coverage Initiated at Jones Trading - MarketBeat
Septerna (SEPN): Valuation Check After Raymond James Buy Rating and S&P Pharma Index Inclusion - Sahm
Septerna, Inc.(NasdaqGM: SEPN) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Septerna, Inc.(NasdaqGM: SEPN) added to NASDAQ Biotechnology Index - marketscreener.com
Septerna’s SEP-631 Study: A Potential Game-Changer in Pharmaceutical Research - MSN
Is New Coverage of Septerna (SEPN) Quietly Reframing Its GPCR Platform’s Risk‑Reward Profile? - simplywall.st
Septerna (NASDAQ:SEPN) Coverage Initiated at Raymond James Financial - Defense World
Septerna (NASDAQ:SEPN) Raised to "Strong-Buy" at Raymond James Financial - MarketBeat
Wall Street Zen Upgrades Septerna (NASDAQ:SEPN) to "Strong-Buy" - MarketBeat
Wall Street Zen Upgrades Septerna (NASDAQ:SEPN) to “Strong-Buy” - Defense World
Why Septerna Inc. stock could be next big winner2025 AllTime Highs & Risk Controlled Stock Pick Alerts - Улправда
Septerna Inc stock hits all-time high at 29.79 USD By Investing.com - Investing.com Nigeria
Septerna (NASDAQ:SEPN) Reaches New 12-Month HighShould You Buy? - MarketBeat
Septerna Inc stock hits all-time high at 29.79 USD - Investing.com
Raymond James Initiates Coverage of Septerna (SEPN) with Strong Buy Recommendation - Nasdaq
Raymond James initiates Septerna stock with Strong Buy rating, $38 target - Investing.com Australia
Raymond James Initiates Coverage on Septerna With Strong Buy Rating, $38 Price Target - marketscreener.com
Raymond James initiates Septerna stock with Strong Buy rating, $38 target By Investing.com - Investing.com India
With Septerna Stock Surging, Have You Considered The Downside? - Trefis
Why Septerna Inc. stock is a must watch in 20252025 Sector Review & Risk Managed Investment Strategies - DonanımHaber
How institutional buying supports Septerna Inc. stockWeekly Earnings Recap & Daily Price Action Insights - Улправда
How Septerna Inc. stock benefits from tech adoptionInsider Selling & Long-Term Investment Growth Plans - Улправда
Septerna, Inc. (NASDAQ:SEPN) Receives $29.25 Average Target Price from Brokerages - Defense World
Septerna (NASDAQ:SEPN) Earns Buy Rating from Analysts at Truist Financial - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at Truist Financial - MarketBeat
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Septerna Inc (SEPN) 재무 분석
Septerna Inc (SEPN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):